Solventum Corporation SOLV
Solventum's post-spin performance collapse is nearly worst-in-class; restoring 3M-era 3-4% growth and 26% margins plus simplifying the portfolio can double shares to $140 by 2027.
Thesis
Trian owns ~5% of Solventum (SOLV), 3M's former Health Care division spun off in April 2024, and argues the company is dramatically underperforming its potential. Inside 3M, Health Care consistently delivered 3-4% organic growth at ~26% EBIT margins for two decades; since the spin, growth has collapsed to ~0.9% and consensus 2025 margins of 20% would mark the 3rd-worst post-spin margin performance of any US large-cap spin-out in a decade (-424bps vs pre-spin pro forma, versus +125bps average for peers). Pre-spin, sell-side analysts valued the business at ~$33bn / $144/share — more than double today's $69. Trian demands the February LRP announcement restore historical performance targets, divest Dental, Health Info Systems and Purification & Filtration (~45% of sales), and commit to disciplined capital allocation. At 3%/26% metrics and a 15x P/E, shares could be worth ~$140 by YE 2027.
SCQA
Solventum, spun from 3M in April 2024, inherited Health Care's #1-positioned franchises that grew 3-4% organically at 26-27% EBIT margins every year for two decades inside 3M — a portfolio of niche, daily-use medical products.
Post-spin, organic growth collapsed to ~0.9% and 2025E EBIT margin of 20% implies a 424bps decline versus pre-spin pro forma — the 3rd-worst spin-out margin performance of any $5bn+ US spin in a decade.
Management must use the February Long Range Plan to set ambitious targets restoring historical 3M-era performance, simplify the portfolio by divesting three non-core segments (~45% of sales), and commit to a dividend, buybacks and disciplined capital allocation.
Restoring 3-4% organic growth and 26% EBIT margins at a 15x NTM P/E implies ~$140/share by year-end 2027 — roughly double today's $69 — with further upside from portfolio simplification and multiple re-rating.
The three reasons
- 1
Solventum's 424bps first-year margin decline would rank 3rd-worst of any US spin in a decade
- 2
Pre-spin sell-side valued SOLV at ~$144/share; shares trade at $69 today — >100% gap
- 3
Restoring 3-4% growth and 26% margins with a 15x P/E implies ~$140/share by YE 2027
Primary demands
- Use the February Long Range Plan announcement to set ambitious targets restoring 3M-era organic growth (3-4%) and EBIT margins (26-27%)
- Right-size overhead costs — Solventum retained ~1,000bps of 3M corporate allocations; reinvest savings in sales, marketing and R&D
- Simplify portfolio by divesting three non-core segments (Dental Solutions, Health Info Systems, Purification & Filtration — ~45% of sales)
- Clarify capital allocation: initiate a dividend once leverage drops below 3x, authorize repurchases, and target 2-3x net leverage range
- Align management compensation with key LRP metrics and shareholder value creation
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- GE HealthCare spin from GE (2023)
- DuPont's sale of Coatings (Axalta, 2012)
- Covidien spin from Tyco (2007)
Notable slides (6)
Notes
Bundle of three documents in one PDF: (1) press release pp.1-3, (2) signed letter to Solventum shareholders pp.4-8, (3) 16-slide deck pp.9-25. Classified as full_deck since the slide presentation is the dominant artifact and the letter/PR explicitly reference slide pages (e.g. 'see page 14 of the attached slide presentation'). Signed 'Trian Fund Management, L.P.' with no individual signatory — author_name left null despite Nelson Peltz being Trian's known founder. Tone is collaborative-analytical in the Trian house style ('initiated dialogues', 'engage', 'work collaboratively') but with urgency language ('alarming', 'unprecedented', 'worst-in-class'). Visible '10XEBITDA.com' watermark suggests the PDF was sourced from a third-party aggregator rather than Trian directly. Precedent-spin benchmarking (slide 9) and allocated-cost comparison (slide 11) are the strongest original analytical contributions.